Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Praxis Precision Medicines (Nasdaq: PRAX) announced on October 1, 2025 that its Compensation Committee granted restricted stock unit awards covering an aggregate of 4,200 shares to three new non‑executive employees under the 2024 Inducement Plan.

The awards were granted as inducements material to the employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, subject to the recipients' continued employment on each vesting date. The 2024 Inducement Plan is reserved exclusively for equity awards to newly hired individuals or those returning after a bona fide break in service.

BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on October 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 4,200 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Contacts:
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

What did Praxis (PRAX) announce on October 2, 2025 about inducement grants?

Praxis disclosed RSU awards of 4,200 shares granted on Oct 1, 2025 to three new non‑executive employees under the 2024 Inducement Plan.

How do the Praxis PRAX restricted stock units vest and when do they vest?

The RSUs vest in four equal annual installments, subject to continued employment on each vesting date.

Why were the Praxis PRAX awards granted under Nasdaq Listing Rule 5635(c)(4)?

They were granted as inducements material to new hires, which Nasdaq Rule 5635(c)(4) permits for newly employed individuals.

Do the Praxis PRAX inducement grants indicate a change to the company’s equity plan?

No. The awards were made under the existing 2024 Inducement Plan, used exclusively for new‑hire equity inducements.

Will the Praxis PRAX RSU grants cause immediate dilution to shareholders?

The press release does not quantify outstanding shares or dilution; it only states an aggregate award of 4,200 shares.

Who received the Praxis PRAX inducement RSUs and were they executives?

The awards were granted to three new non‑executive employees; no executive officers were identified in the release.